Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan, +18

The Lancet

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Xu-Hua Guan, Yu-Hua Li, +24

The Lancet

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang, +16

The Lancet Infectious Diseases

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Shipo Wu, Gongxun Zhong, Jun Zhang, +22

Nature Communications

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

Busen Wang, Jianhua Li, Shipo Wu, +9

Emerging Microbes & Infections

VaccinationVirus EpidemiologyViral DiagnosticsMedicinePathogenesis +11

Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models

Qiang Guo, Jasper Fuk‐Woo Chan, Vincent Kwok‐Man Poon, +15

The Journal of Infectious Diseases

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

Rong Tang, Hui Zheng, Busen Wang, +22

The Lancet Respiratory Medicine

VaccinationVaccine SafetyVaccine DevelopmentPhase 4Immunology +5

Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus

Zhe Zhang, Zhenghao Zhao, Shipo Wu, +6

Frontiers in Immunology

VaccinationMucosal VaccinationVaccine DevelopmentRobust Immune ResponseVaccine Target +11

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination

Xiangyang Chi, Yingying Guo, Guanying Zhang, +26

Signal Transduction and Targeted Therapy

PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71

Zhe Zhang, Busen Wang, Shipo Wu, +6

Virology

Molecular VirologyAntiviral AgentsMedicineImmunologyAntiviral Drug Development +7